Globally, 3 out of 5 persons lose their lives to chronic inflammatory conditions, such as diabetes, cardiovascular disorders, cancer, chronic respiratory diseases, skin diseases, renal diseases and obesity. Inflammatory diseases are the most prevailing cause of death worldwide and the numbers keep rising.
The network focuses on reducing the burden of infectious and inflammatory diseases caused by pathogens, damaged cells, toxic compounds or radiation in order to develop new diagnostic and treatment technologies.
As a society, we need more knowledge about the correlation between e.g. inflammation and development of cancer, about biomarkers and about molecular mechanisms of autoimmunity in e.g. rheumatological conditions - not to mention chronic mucosal inflammation. In the inflammation network we collaborate interdisciplinearily in order to find answers.
We comprise a wide range of researchers with interest in diagnostic methods, epidemiological data, inflammatory markers and intracellular pathways, understanding of cell population and tissue structures, among others.
Karina Dalsgaard Sørensen
Cancer has long been perceived as a disease of the human genome. However, recent lines of evidence point to a more prominent role of the human microbiota in cancer development and progression. This novel insight has significant clinical implications for patient treatment and early detection of cancer. Nevertheless, the field of microbiome research in cancer is still in its infancy and its relevance to prostate carcinogenesis is far from being understood.
A recent study aimed to map the microbial composition within malignant and benign prostate tissue from patients suffering from prostate cancer, in the hope of finding associations between cancer development/progression and the composition of the prostate tissue microbiome. The authors identified several microbial species to be in dysbiosis within malignant compared to benign prostate tissue. Microbial dysbiosis was also associated with altered immune regulation within the prostate tissue.
These findings point to the future possibility of using certain microbial species as diagnostic/prognostic biomarkers in prostate cancer, or even as novel treatment targets for achieving better response. Immunomodulatory effects of certain species could also be targets for future immunotherapy.
Salachan et al.: Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling